Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Gastroenterology. 2018 May;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064. Epub 2018 Feb 6.
BACKGROUND & AIMS: Society guidelines differ in their recommendations for surveillance to detect early-stage hepatocellular carcinoma (HCC) in patients with cirrhosis. We compared the performance of surveillance imaging, with or without alpha fetoprotein (AFP), for early detection of HCC in patients with cirrhosis.
Two reviewers searched MEDLINE and SCOPUS from January 1990 through August 2016 to identify published sensitivity and specificity of surveillance strategies for overall and early detection of HCC. Pooled estimates were calculated and compared using the DerSimonian and Laird method for a random effects model. The study was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis guidelines.
Thirty-two studies (comprising 13,367 patients) characterized sensitivity of imaging with or without AFP measurement for detection of HCC in patients with cirrhosis. Ultrasound detected any stage HCC with 84% sensitivity (95% confidence interval [CI] 76%-92%), but early-stage HCC with only 47% sensitivity (95% CI 33%-61%). In studies comparing ultrasound with vs without AFP measurement, ultrasound detected any stage HCC with a lower level of sensitivity than ultrasound plus AFP measurement (relative risk [RR] 0.88; 95% CI 0.83-0.93) and early-stage HCC with a lower level of sensitivity than ultrasound plus AFP measurement (RR 0.81; 95% CI 0.71-0.93). However, ultrasound alone detected HCC with a higher level of specificity than ultrasound plus AFP measurement (RR 1.08; 95% CI 1.05-1.09). Ultrasound with vs without AFP detected early-stage HCC with 63% sensitivity (95% CI 48%-75%) and 45% sensitivity (95% CI 30%-62%), respectively (P = .002). Only 4 studies evaluated computed tomography or magnetic resonance image-based surveillance, which detected HCC with 84% sensitivity (95% CI 70%-92%).
We found ultrasound alone has a low sensitivity to detect early stage HCC in patients with cirrhosis. Addition of AFP to ultrasound significantly increases sensitivity of early HCC detection in clinical practice.
社会指南在建议用于检测肝硬化患者早期肝细胞癌(HCC)的监测方法方面存在差异。我们比较了联合或不联合甲胎蛋白(AFP)的监测成像在肝硬化患者中早期检测 HCC 的性能。
两位审查员搜索了 MEDLINE 和 SCOPUS 数据库,从 1990 年 1 月至 2016 年 8 月,以确定发表的监测策略对整体和早期 HCC 检测的敏感性和特异性。使用随机效应模型的 DerSimonian 和 Laird 方法计算并比较汇总估计值。本研究按照系统评价和荟萃分析的首选报告项目进行。
32 项研究(共 13367 例患者)描述了联合或不联合 AFP 测量的影像学检查检测肝硬化患者 HCC 的敏感性。超声检查对任何阶段 HCC 的检出率为 84%(95%置信区间[CI]为 76%-92%),但早期 HCC 的检出率仅为 47%(95%CI 为 33%-61%)。在比较超声检查与 AFP 测量的研究中,超声检查对任何阶段 HCC 的检出率低于联合 AFP 测量的超声检查(相对风险[RR]0.88;95%CI 0.83-0.93),对早期 HCC 的检出率低于联合 AFP 测量的超声检查(RR 0.81;95%CI 0.71-0.93)。然而,单独使用超声检查检测 HCC 的特异性高于联合 AFP 测量的超声检查(RR 1.08;95%CI 1.05-1.09)。联合 AFP 检查检测早期 HCC 的敏感性为 63%(95%CI 48%-75%),而不联合 AFP 检查的敏感性为 45%(95%CI 30%-62%)(P=0.002)。只有 4 项研究评估了基于计算机断层扫描或磁共振成像的监测,其对 HCC 的检出率为 84%(95%CI 70%-92%)。
我们发现单独使用超声检查对肝硬化患者早期 HCC 的检出率较低。联合 AFP 可显著提高临床实践中早期 HCC 检测的敏感性。